無料セミナー : 2018年11月27日『オンコロジーにおける遺伝子治療・CAR-T細胞療法』 DelveInsight Business Research LLP共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界における癌ワクチン市場 & 治験の考察

Global Cancer Vaccine Market & Clinical Trial Insight 2025

発行 PNS Pharma 商品コード 696694
出版日 ページ情報 英文 700 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界における癌ワクチン市場 & 治験の考察 Global Cancer Vaccine Market & Clinical Trial Insight 2025
出版日: 2018年09月12日 ページ情報: 英文 700 Pages
概要

当レポートでは、世界の癌ワクチン市場について調査し、癌ワクチンの開発・市販化に関連した臨床・非臨床パラメーターについての包括的な考察を提供しています。

第1章 癌ワクチンのイントロダクション

第2章 癌ワクチンのメカニズム

第3章 世界における癌ワクチン市場の概要

第4章 オーダーメイド癌ワクチン:次の成長フロンティア

第5章 オーダーメイド癌ワクチン:市場の現況 & 進歩

第6章 癌ワクチンの開発 & マーケティングに対するFDAのガイドライン

第7章 世界における癌ワクチンの臨床パイプライン概要

  • 適応症別
  • 作用機序別
  • 薬剤クラス別
  • 患者セグメント別
  • 処方別
  • 企業別

第8章 世界における膀胱癌ワクチンの臨床パイプライン:フェーズ・企業別

第9章 市販の膀胱癌ワクチン:臨床考察

第10章 世界における血液癌ワクチンの臨床パイプライン:フェーズ・企業別

第11章 世界における骨癌ワクチンの臨床パイプライン:フェーズ・企業別

第12章 世界における脳腫瘍ワクチンの臨床パイプライン:フェーズ・企業別

第13章 世界における乳癌ワクチンの臨床パイプライン:フェーズ・企業別

第14章 世界における子宮頸癌ワクチンの臨床パイプライン:フェーズ・企業別

第15章 市販の子宮頸癌ワクチン臨床考察

第16章 世界における大腸癌ワクチンの臨床パイプライン:フェーズ・企業別

第17章 世界における腎臓癌ワクチンの臨床パイプライン:フェーズ・企業別

第18章 市販の腎臓癌ワクチン臨床考察

第19章 世界における肝臓癌ワクチンの臨床パイプライン:フェーズ・企業別

第20章 世界における肺癌ワクチンの臨床パイプライン:フェーズ・企業別

第21章 世界における中皮腫ワクチンの臨床パイプライン:フェーズ・企業別

第22章 世界における頭頚部癌ワクチンの臨床パイプライン:フェーズ・企業別

第23章 世界における小細胞肺癌ワクチンの臨床パイプライン:フェーズ・企業別

第24章 市販の小細胞肺癌ワクチン臨床考察

第25章 世界における子宮癌ワクチンの臨床パイプライン:フェーズ・企業別

第26章 世界における前立腺癌ワクチンの臨床パイプライン:フェーズ・企業別

第27章 市販の前立腺癌ワクチン臨床考察

第28章 世界における膵臓癌ワクチンの臨床パイプライン:フェーズ・企業別

第29章 市販の膵臓癌ワクチン臨床考察

第30章 世界における皮膚癌ワクチンの臨床パイプライン:フェーズ・企業別

第31章 市販の皮膚癌ワクチン臨床考察

第32章 世界における多発性癌ワクチンの臨床パイプライン:フェーズ・企業別

第33章 市販の多発性癌ワクチン臨床考察

第34章 競合情勢

  • Advaxis
  • AVAX Technologies
  • Dendreon Corporation
  • Galena Biopharma
  • GlaxoSmithKline
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Inovio Pharmaceuticals
  • KAEL-GemVax
  • Liponova
  • MedImmune
  • Merck
  • NeoStem Oncology
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novartis
  • Peregrine Pharmaceuticals
  • Recombio
  • Roche
  • Sanofi
  • Seattle Genetics
  • Valeant Pharmaceuticals
目次

"Global Cancer Vaccine Market & Clinical Trial Insight 2025" Report Highlight:

  • Global Cancer Vaccine market Opportunity: US$ 15 Billion Opportunity
  • Personalized Cancer Vaccine: The Next growth Frontier
  • Global Cancer Vaccine Clinical insight by Indication & Phase of Development
  • Global Cancer Vaccine Pipeline: 369 Cancer Vaccines
  • Marketed Cancer Vaccines: 17 Cancer Vaccines
  • Maximum Vaccines in Pipeline for Brain & Breast Cancer: 43 Cancer Vaccines
  • Regulatory Landscape

Global cancer vaccine market opportunity is expected to surpass US$ 15 Billion by 2025 as per finding in new research report “Global Cancer Vaccine Market & Clinical Trial Insight 2025” published by PNS Pharma. In recent years, cancer vaccine segment as emerged as next growth frontier for the various stake holders involved in the research, development and commercialization of cancer therapeutics. The market for cancer therapeutics is growing at significant rates and it has already occupied a major share in the overall pharmaceutical market.

Vaccines have had a good reputation when it comes to their safety and therapeutic outcome. The concept of vaccination has today paved a new path for treatment of complex disease like cancer, the cure for which is still highly limited to conventional therapeutics. However, with the emergence of immunotherapy, the cancer therapy segment has also advanced to a whole new level.

The application of the concept of vaccination to complex disease like cancer has grabbed immense attention in both academia and industries. Multiple clinical studies have shown that an ideal vaccine for cancer is in fact possible with the help of modern immunotherapy and advanced therapy. However, the study has further being extended with rigorous effort being put in the development of personalized cancer vaccine which are anticipated to have even better therapeutic outcome than cancer vaccines .

Owing to the advancement in science and technology along with the emergence of advanced computing, few cancer vaccines like cervarix for cervical cancer and provenge for prostate cancer have already entered the market. Both the vaccines are therapeutic vaccines which have shown excellent outcome in the clinical trials. The emergence of genome sequencing and ability to identify and target neo - antigens has led to the possibility of these vaccines being developed for many types of cancer in a more personalized form in the future.

The cancer vaccine pipeline is expected to increase at tremendous rates in coming years. As large numbers of cancer vaccines are entering in various phases of clinical trials, due to which cancer market will soon observe a boost. However, the novelty of cancer vaccines makes it difficult for the standardization of clinical trials, because the criteria's required to quantify its effectiveness are not completely discovered, this cause loss of valuable time. Moreover, the present day methods are standardized for conventional cancer therapeutic methods like chemotherapy, radiotherapy and surgery, which are not applicable for cancer vaccines due to their different mode of actions. In near future, researchers will find the solution for this problem and it will decrease the winding time.

“Global Cancer Vaccine Market & Clinical Trial Insight 2025” report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of cancer vaccines. As per report findings, there are 17 cancer vaccines commercially available in the market and more than 350 in the clinical pipeline. Most of the cancer vaccines in clinical pipeline are in Preclinical & Phase - II trials followed by Phase - I/II trials. More than 5 new cancer vaccines are further expected to enter the market in next 10 years.

Table of Contents

1. Introduction to Cancer Vaccines

2. Mechanism of Cancer Vaccines

  • 2.1. Idiotype Cancer Vaccine Mechanism
  • 2.2. Cellular Cancer Vaccines Mechanism
  • 2.3. Ganglioside Antigens based Cancer Vaccines Mechanism
  • 2.4. Peptide Cancer Vaccine Mechanism
  • 2.5. Tumor Host Interaction Cancer Vaccine Mechanism

3. Global Cancer Vaccines Market Overview

  • 3.1. Current Scenario
  • 3.2. Future Outlook

4. Personalized Cancer Vaccine: The Next growth Frontier

  • 4.1. The Possibility of a Personalized Cancer Vaccine
  • 4.2. An Insight into its Current Clinical Status

5. Personalized Cancer Vaccine: Current Market Scenario & Advancements

  • 5.1. Breakthrough in Research & Development
  • 5.2. Increasing Investments
  • 5.3. Integration of mRNA Technology
  • 5.4. Collaborations & Ventures
  • 5.5. Advancement in Technology

6. FDA Guideline for the Development & Marketing of Cancer Vaccines

  • 6.1. Considerations for Both Early and Late Phase Clinical Trials
    • 6.1.1. Patient Population
    • 6.1.2. Monitoring The Immune Response
    • 6.1.3. Biomarkers As Evidence Of Efficacy
    • 6.1.4. Adjuvants Used To Stimulate Immune Response
    • 6.1.5. Multi-Antigen Vaccines
    • 6.1.6. Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
    • 6.1.7. Concomitant And Subsequent Therapies
  • 6.2. Considerations for Early Phase Clinical Trials
    • 6.2.1. Starting Dose And Dosing Schedule
    • 6.2.2. Booster And Maintenance Therapy
    • 6.2.3. Dose Escalation
    • 6.2.4. Single-Arm Versus Randomized Phase 2 Trials In Early Development
  • 6.3. Considerations For Late Phase Clinical Trials
    • 6.3.1. Safety Profile From Early Phase Clinical Trials
    • 6.3.2. Endpoints
    • 6.3.3. Statistical Issues
    • 6.3.4. Control Issues
    • 6.3.5. Delayed Vaccine Effect
    • 6.3.6. Autologous Vaccine Trials
    • 6.3.7. Accelerated Approval Regulations

7. Global Cancer Vaccines Clinical Pipeline Overview

  • 7.1. By Indication
  • 7.2. By Mechanism of Action
  • 7.3. By Drug Class
  • 7.4. By Patient Segment
  • 7.5. By Formulation
  • 7.6. By Company

8. Global - Bladder Cancer Vaccine Clinical Pipeline by Phase & Company

  • 8.1. Phase-I/II

9. Marketed Bladder Cancer Vaccine Clinical Insight

  • 9.1. BCG Bladder Cancer Vaccine - sanofi pasteur
  • 9.2. Bladder Cancer Vaccine - Organon Teknika
  • 9.3. Bladder Cancer Vaccine - ID Biomedical

10. Global - Blood Cancer Vaccine Clinical Pipeline by Phase & Company

  • 10.1. Research
  • 10.2. Preclinical
  • 10.3. Phase-I
  • 10.4. Phase-I/II
  • 10.5. Phase-II

11. Global - Bone Cancer Vaccine Clinical Pipeline by Phase & Company

  • 11.1. Phase-II
  • 11.2. Phase-III

12. Global - Brain Cancer Vaccine Clinical Pipeline by Phase & Company

  • 12.1. Unknown
  • 12.2. Research
  • 12.3. Preclinical
  • 12.4. Phase-I
  • 12.5. Phase-I/II
  • 12.6. Phase-II
  • 12.7. Phase-III

13. Global - Breast Cancer Vaccine Clinical Pipeline by Phase & Company

  • 13.1. Research
  • 13.2. Preclinical
  • 13.3. Phase-I
  • 13.4. Phase-I/II
  • 13.5. Phase-II
  • 13.6. Phase-II/III
  • 13.7. Phase-III

14. Global - Cervical Cancer Vaccine Clinical Pipeline by Phase & Company

  • 14.1. Preclinical
  • 14.2. Clinical
  • 14.3. Phase-I
  • 14.4. Phase-II
  • 14.5. Phase-III

15. Marketed Cervical Cancer Vaccine Clinical Insight

  • 15.1. Cervarix

16. Global - Colorectal Cancer Vaccine Clinical Pipeline by Phase & Company

  • 16.1. Research
  • 16.2. Preclinical
  • 16.3. Phase-I
  • 16.4. Phase-I/II
  • 16.5. Phase-II
  • 16.6. Phase-II/III
  • 16.7. Phase-III

17. Global - Kidney Cancer Vaccine Clinical Pipeline by Phase & Company

  • 17.1. Preclinical
  • 17.2. Phase-I
  • 17.3. Phase-II
  • 17.4. Phase-III

18. Marketed Kidney Cancer Vaccine Clinical Insight

  • 18.1. Vitespen (Oncophage)
  • 18.2. Dendritic Cell Vaccine (CreaVax-HCC, CreaVax-PC & CreaVax-RCC)
  • 18.3. Renal Cell Carcinoma Vaccine (Reniale)

19. Global - Liver Cancer Vaccine Clinical Pipeline by Phase & Company

  • 19.1. Phase-I/II
  • 19.2. Phase-II
  • 19.3. Phase-III

20. Global - Lung Cancer Vaccine Clinical Pipeline by Phase & Company

  • 20.1. Preclinical

21. Global - Mesothelioma Vaccine Clinical Pipeline by Phase & Company

  • 21.1. Phase-I
  • 21.2. Phase-II/III

22. Global - Head And Neck Cancer Vaccine Clinical Pipeline by Phase & Company

  • 22.1. Preclinical
  • 22.2. Phase-I
  • 22.3. Phase-I/II
  • 22.4. Phase-II

23. Global - Non Small Cell Lung Cancer Vaccine Clinical Pipeline by Phase & Company

  • 23.1. Research
  • 23.2. Clinical
  • 23.3. Phase-I
  • 23.4. Phase-I/II
  • 23.5. Phase-II
  • 23.6. Phase-II/III
  • 23.7. Phase-III
  • 23.8. Preregistration

24. Marketed Non Small Cell Lung Cancer Vaccine Clinical Insight

  • 24.1. Cadi 05(Immuvac & Mycidac-C)
  • 24.2. Racotumomab (Vaxira)
  • 24.3. Epidermal Growth Factor Cancer Vaccine - Bioven

25. Global - Ovarian Cancer Vaccine Clinical Pipeline by Phase & Company

  • 25.1. Preclinical
  • 25.2. Phase-I
  • 25.3. Phase-I/II
  • 25.4. Phase-II
  • 25.5. Phase-III

26. Global - Prostate Cancer Vaccine Clinical Pipeline by Phase & Company

  • 26.1. Research
  • 26.2. Preclinical
  • 26.3. Phase-I
  • 26.4. Phase-I/II
  • 26.5. Phase-II
  • 26.6. Phase-III

27. Marketed Prostate Cancer Vaccine Clinical Insight

  • 27.1. Sipuleucel-T (Provenge)

28. Global - Pancreatic Cancer Vaccine Clinical Pipeline by Phase & Company

  • 28.1. Preclinical
  • 28.2. Phase-I
  • 28.3. Phase-I/II
  • 28.4. Phase-II
  • 28.5. Phase-III

29. Marketed Pancreatic Cancer Vaccine Clinical Insight

  • 29.1. Tertomotide (LucaVax)

30. Global - Skin Cancer Vaccine Clinical Pipeline by Phase & Company

  • 30.1. Preclinical
  • 30.2. Phase-I
  • 30.3. Phase-I/II
  • 30.4. Phase-II
  • 30.5. Phase-III
  • 30.6. Preregistration

31. Marketed Skin Cancer Vaccine Clinical Insight

  • 31.1. Melanoma Vaccine (MVax)
  • 31.2. Melanoma Vaccine (Melacine)

32. Global - Multiple Cancer Vaccine Clinical Pipeline by Phase & Company

  • 32.1. Research
  • 32.2. Preclinical
  • 32.3. Clinical
  • 32.4. Phase-I
  • 32.5. Phase-I/II
  • 32.6. Phase-II
  • 32.7. Phase-III
  • 32.8. Registered

33. Marketed Multiple Cancer Vaccine Clinical Insight

  • 33.1. Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)
  • 33.2. Human Papillomavirus Vaccine Recombinant Quadrivalent (Gardasil & Silgard)
  • 33.3. Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

34. Competitive Landscape

  • 34.1. Advaxis
  • 34.2. AVAX Technologies
  • 34.3. Dendreon Corporation
  • 34.4. Galena Biopharma
  • 34.5. GlaxoSmithKline
  • 34.6. ImmunoCellular Therapeutics
  • 34.7. ImmunoGen
  • 34.8. Inovio Pharmaceuticals
  • 34.9. KAEL-GemVax
  • 34.10. Liponova
  • 34.11. MedImmune
  • 34.12. Merck
  • 34.13. NeoStem Oncology
  • 34.14. NewLink Genetics
  • 34.15. Northwest Biotherapeutics
  • 34.16. Novartis
  • 34.17. Peregrine Pharmaceuticals
  • 34.18. Recombio
  • 34.19. Roche
  • 34.20. Sanofi
  • 34.21. Seattle Genetics
  • 34.22. Valeant Pharmaceuticals

List of Figures

  • Figure 1-1: Categorization & Function of Cancer Vaccines
  • Figure 2-1: Classification of Different Types of Cancer vaccines
  • Figure 3-1: Global - Cancer Vaccines Market Opportunity (US$ Billion), 2018-2025
  • Figure 3-2: Examples of Commercially Available Cancer Vaccines
  • Figure 4-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
  • Figure 4-2: Advantages of Targeting Neo - Antigens in Cancer Vaccine Production
  • Figure 5-1: Investments Generated by Key Market Players in the Personalized Cancer Segment (US$ Million), 2018
  • Figure 7-1: Global - Bladder Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-2: Global - Bladder Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-3: Global - Blood Cancer Vaccine Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-4: Global - Blood Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-5: Global - Bone Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7 6: Global - Bone Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-7: Global - Brain Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-8: Global - Brain Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-9: Global - Breast Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-10: Global - Breast Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-11: Global - Cervical Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-12: Global - Cervical Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-13: Global - Colorectal Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-14: Global - Colorectal Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-15: Global - Kidney Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-16: Global - Kidney Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-17: Global - Liver Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-18: Global - Liver Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-19: Global - Masothelioma Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-20: Global - Masothelioma Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-21: Global - Head and Neck Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-22 Global - Head and Neck Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-23: Global - Non Small Lung Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-24: Global - Non Small Lung Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-25: Global - Ovarian Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-26: Global - Ovarian Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-27: Global - Prostate Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-28: Global - Prostate Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-29: Global - Pancreatic Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-30: Global - Pancreatic Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-31: Global - Skin Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-32: Global - Skin Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-33: Global - Multiple Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-34: Global - Multiple Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-35: Total Global - Multiple Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
  • Figure 7-36: Total Global - Multiple Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
  • Figure 7-37: Global -Cancer Vaccines Clinical Pipeline by Mechanism of Action (%), 2018 Till 2025
  • Figure 7-38: Global -Cancer Vaccines Clinical Pipeline by Mechanism of Action (Number), 2018 Till 2025
  • Figure 7-39: Global - Cancer Vaccines Clinical Pipeline by Drug Class (%), 2018 Till 2025
  • Figure 7-40: Global - Cancer Vaccines Clinical Pipeline by Drug Class (Number), 2018 Till 2025
  • Figure 7-41: Global - Cancer Vaccines Clinical Pipeline by Patient Segment (%), 2018 Till 2025
  • Figure 7-42: Global - Cancer Vaccines Clinical Pipeline by Patient Segment (Number), 2018 Till 2025
  • Figure 7-43: Global - Cancer Vaccines Clinical Pipeline by Formulation (%), 2018 Till 2025
  • Figure 7-44: Global - Cancer Vaccines Clinical Pipeline by Formulation (Number), 2018 Till 2025
  • Figure 7-45: Global - Cancer Vaccines Clinical Pipeline by Company (%), 2018 Till 2025
  • Figure 7-46: Global - Cancer Vaccines Clinical Pipeline by Company (%), 2018 Till 2025
Back to Top